TriangleNCT01760655 · OUTCOME
Immune Reconstitution at Day +28
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- cells/mm³
- Interval / dispersion
- Standard Deviation
- Time frame
- Up to 1 year
What was measured
CD4 and CD8 values at Day +28. Reported as mean (standard deviation).
Analysis population: Participants surviving to Day +28 with evaluable data. This excludes the one subject who was a graft failure and anyone who died before 28 days.
Groups in this outcome
Treatment (RIC and allogeneic PBSCT)
REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10. TRANSPLANT: Patients undergo allogeneic PBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28 Fludarabine phosphate: Given IV Busulfan: Given IV Total-Body Irradiation: Undergo TBI Therapeutic Allogeneic Lymphocytes: Undergo DLI Cyclophosphamide: Given IV Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSCT Tacrolimus: Given IV Mycophenolate Mofetil: Given IV Laboratory Biomarker Analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (RIC and allogeneic PBSCT) | 56 |
Reported measurements
CD3/4 at Day +28
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (RIC and allogeneic PBSCT) | 66.9 | 80.5 | Not reported | Not reported | Not reported |
CD3/8 at Day +28
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (RIC and allogeneic PBSCT) | 109.9 | 137.4 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 80.5
- value
- 66.9
- title
- CD3/4 at Day +28
- categories
- measurements
- group Id
- OG000
- spread
- 137.4
- value
- 109.9
- title
- CD3/8 at Day +28
- denoms
- counts
- group Id
- OG000
- value
- 56
- units
- Participants
- description
- CD4 and CD8 values at Day +28. Reported as mean (standard deviation).
- dispersion Type
- Standard Deviation
- groups
- description
- REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10. TRANSPLANT: Patients undergo allogeneic PBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28 Fludarabine phosphate: Given IV Busulfan: Given IV Total-Body Irradiation: Undergo TBI Therapeutic Allogeneic Lymphocytes: Undergo DLI Cyclophosphamide: Given IV Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSCT Tacrolimus: Given IV Mycophenolate Mofetil: Given IV Laboratory Biomarker Analysis: Correlative studies
- id
- OG000
- title
- Treatment (RIC and allogeneic PBSCT)
- param Type
- MEAN
- population Description
- Participants surviving to Day +28 with evaluable data. This excludes the one subject who was a graft failure and anyone who died before 28 days.
- reporting Status
- POSTED
- time Frame
- Up to 1 year
- title
- Immune Reconstitution at Day +28
- type
- SECONDARY
- unit Of Measure
- cells/mm³
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice